菜单

Perspectives

What economic or market trends are having the biggest impact on CDMO capacity and pipelines in 2025, and what will 2026 bring?
Nov. 03, 2025
What economic or market trends are having the biggest impact on CDMO capacity and pipelines in 2025, and what will 2026 bring?

In November Pharma’s Almanac roundtables, Dr. Chris Chen, CEO of WuXi Biologics, shared his insights on the market trend of global CDMO industry. Learn more, click here.

 

There are two major trends shaping the industry. The first is the evolving landscape of biological products. The growth engine is gradually shifting from traditional mAbs to novel antibodies with more complex mechanisms and higher technological barriers, including bispecific antibodies (bsAbs) and ADCs. This surge in demand is driving CDMOs to develop new technology platforms and enhance our service capabilities to effectively support clients’ innovative therapies.

 

The second trend is the shift in industry structure. We have observed that an increasing number of biotech companies now possess the capabilities to bring their products to market, without the need to license or sell product rights at the early R&D stage. And they often choose to outsource certain tasks to CDMOs, as they lack comprehensive experience in chemistry, manufacturing, and controls (CMC) and manufacturing. Service providers like WuXi Biologics that offer integrated platforms spanning discovery, development and manufacturing are uniquely positioned to enable them and create greater value across the industry.